FAS Specific Neutra™ Antibody Products

Are you grappling with prolonged drug development timelines or inconsistent results in modulating Fas-mediated apoptosis? Creative Biolabs' FAS specific Neutra™ antibody products leverage advanced protein engineering and high-affinity epitope targeting to deliver precise, reproducible tools for studying apoptosis regulation, accelerating therapeutic discovery in autoimmune disorders and cancer.

Introduction to FAS

Fas cell surface death receptor (FAS), also known as CD95, is a transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It acts as a master regulator of apoptosis, transmitting extrinsic death signals upon binding to its cognate ligand, Fas ligand (FASL). FAS is ubiquitously expressed in immune cells, epithelial tissues, and transformed cells, playing pivotal roles in immune homeostasis, tissue remodeling, and tumor suppression. Dysregulation of FAS signaling is implicated in autoimmune diseases, cancer immune evasion, and degenerative conditions.

• Structure

The FAS receptor comprises three functional domains: an extracellular cysteine-rich homology (CRH) domain for ligand binding, a transmembrane helix, and an intracellular death domain (DD) essential for recruiting apoptosis-initiating adaptors like FADD. FAS forms homotrimers upon FASL engagement, triggering conformational changes that facilitate DD oligomerization and caspase activation. Structural studies reveal that FAS trimerization stabilizes the intracellular DISC (death-inducing signaling complex), enabling caspase-8 activation and subsequent apoptosis execution.

• Related Signaling Pathways

FAS activation initiates the extrinsic apoptosis pathway via caspase-8/10 cleavage, culminating in DNA fragmentation and cell death. Cross-talk with intrinsic apoptosis pathways (e.g., Bcl-2/Bax) amplifies death signals under stress conditions. FAS also modulates non-apoptotic pathways, including NF-κB and MAPK, influencing inflammatory responses and cell proliferation. Notably, FASL-FAS interactions regulate immune cell cytotoxicity and clonal deletion of autoreactive lymphocytes, highlighting its dual role in immune tolerance and pathogen defense.

Fig.1 Apoptotic signaling via FAS/FASL.¹

• Related Diseases

Aberrant FAS signaling is central to autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where defective apoptosis permits survival of autoreactive cells. Conversely, somatic FAS mutations or epigenetic silencing in cancers (e.g., glioblastoma, melanoma) confer resistance to immune-mediated killing. FAS overexpression in degenerative diseases like Alzheimer's exacerbates neuronal loss, underscoring its therapeutic relevance across diverse pathologies.

Applications of Anti-FAS Neutralizing Antibodies

• Therapeutic Intervention in Autoimmunity

Neutralizing FAS antibodies mitigate pathological apoptosis in autoimmune diseases by blocking FASL-mediated cell death. In SLE models, these antibodies reduce lymphopenia and organ damage, restoring immune equilibrium.

• Oncology: Overcoming Immune Evasion

Agonistic anti-FAS antibodies reactivate apoptosis in FAS-deficient tumors, synergizing with checkpoint inhibitors to enhance T-cell-mediated tumor clearance. Preclinical studies in colorectal cancer demonstrate tumor regression via caspase-3 activation.

• Toxicology and Drug Safety Screening

Anti-FAS antibodies quantify apoptosis in hepatotoxicity and cardiotoxicity assays, improving predictive accuracy for drug-induced organ damage. This supports compliant safety profiling during drug development.

Our Anti-FAS Antibodies

Neutralizing antibodies targeting FAS block FASL binding or induce receptor clustering to modulate apoptosis. Key applications include:

- Inhibition of Apoptosis: Protecting healthy cells in autoimmune or inflammatory conditions.

- Enhancement of Apoptosis: Sensitizing malignant cells to cytotoxic therapies.

Creative Biolabs' FAS specific antibodies exhibit unparalleled specificity for conformational epitopes, validated in flow cytometry, immunofluorescence, and functional apoptosis assays. Engineered for low off-target binding and high stability, these antibodies are ideal for preclinical therapeutic development and mechanistic studies.

Creative Biolabs offers FAS specific Neutra™ antibody products that empower researchers to dissect apoptosis mechanisms and pioneer transformative therapies. Contact our scientific team today to explore tailored solutions for your project.

REFERENCE

1. Yamada, Akiko, et al. "Dual role of Fas/FasL-mediated signal in peripheral immune tolerance." Frontiers in immunology 8 (2017): 403. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2017.00403